Frey's syndrome and botulinum toxin type A: duration of efficacy and patient satisfaction

2015 ◽  
Vol 30 (5) ◽  
pp. 907-909 ◽  
Author(s):  
P. Dessart ◽  
E. Truchot ◽  
H. Maillard
2002 ◽  
Vol 12 (3) ◽  
pp. 174-178 ◽  
Author(s):  
V. Tugnoli ◽  
R. Marchese Ragona ◽  
R. Eleopra ◽  
R. Quatrale ◽  
J. G. Capone ◽  
...  

2001 ◽  
Vol 24 (6) ◽  
pp. 297-302 ◽  
Author(s):  
S. Rodopoulou ◽  
E. Keramidas ◽  
N. Metaxotos ◽  
G. Tagaris ◽  
E. Tsati ◽  
...  

2015 ◽  
Vol 4 (11) ◽  
pp. 1639-1650 ◽  
Author(s):  
Shang Xie ◽  
Kan Wang ◽  
Tao Xu ◽  
Xue‐Sheng Guo ◽  
Xiao‐Feng Shan ◽  
...  

2017 ◽  
Vol 92 (6) ◽  
pp. 891-892
Author(s):  
Gustavo Vieira Gualberto ◽  
Felipe Mauricio Soeiro Sampaio ◽  
Natália Augusta Brito Madureira

1998 ◽  
Vol 107 (1) ◽  
pp. 52-55 ◽  
Author(s):  
Ollivier Laccourreye ◽  
Luca Muscatelo ◽  
Carole Naude ◽  
Brigitte Bonan ◽  
Daniel Brasnu

Fourteen patients with severe Frey's syndrome (occurring after conservative parotidectomy) managed with intracutaneous injection of botulinum toxin type A were prospectively evaluated. Results were analyzed for effectiveness, complications, and adverse effects. Complications were not encountered. The only adverse effect noted was a temporary and slight partial paresis of the upper lip of 3 months' duration in 2 patients. Permanent paresis was not encountered. Frey's syndrome was always controlled within 2 days following the intracutaneous injection of botulinum toxin A. Frey's syndrome recurrence was not encountered with a follow-up duration that varied from 3 to 9 months (mean follow-up 7 months). This preliminary report confirmed that in patients who have Frey's syndrome after conservative parotidectomy, the intracutaneous injection of botulinum toxin is a valuable treatment option that should be further investigated.


Sign in / Sign up

Export Citation Format

Share Document